GSK to acquire Affinivax in $3.3 billion deal

Tuesday, 31. May 2022 08:36

GlaxoSmithKline plc (GSK) announced on Tuesday that it will acquire clinical-stage biopharmaceutical company Affinivax, Inc. "for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones."

According to the company's statement, "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines."

"The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said Dr. Hal Barron, Chief Scientific Officer and President R&D at GSK.

Related Links: GlaxoSmithKline PLC
Baha Breaking News (BBN) / JG